BioRestorative Therapies, Inc. 8-K

What Happened
BioRestorative Therapies, Inc. (BRTX) filed an 8‑K on July 16, 2026 disclosing significant executive and board changes. On July 13, 2026, President/CEO/Chair Lance Alstodt and CFO Robert Kristal each submitted immediate resignations asserting they resigned for “Good Reason” under their employment agreements, citing an asserted “Change in Control.” The Board has acknowledged the resignations for record purposes but does not concede their validity and has authorized a special‑counsel investigation. Katharyn Field was appointed CEO and President effective July 13, 2026 and named interim CFO, Treasurer and Secretary pending a permanent CFO search. The Board also elected Esha Randhawa (July 13) and Steven Brown (July 14) to fill director vacancies and reconstituted committee memberships.

Key Details

• Employment‑agreement amendments (filed as Exhibits 10.1–10.3) dated July 8, 2026 limit certain severance and equity‑vesting protections to Change‑in‑Control events of the merger/asset‑sale type (clause (iii)), rather than applying on board composition or >50% ownership changes. Definitions of “Change in Control” and “Good Reason” were not amended.
• Messrs. Alstodt and Kristal claim their resignations qualify as “Good Reason” under clause (ii); if so, they would seek aggregate cash severance of about $2.85 million, acceleration of equity awards, and continued benefits.
• The Board has suspended any payments under the Employment Agreements (except accrued unpaid base salary and amounts required by law) pending the special‑counsel investigation.
• Director changes: David Rosa resigned July 11, 2026; Esha Randhawa (appointed to Audit Committee and Chair of Nominating & Governance) and Steven Brown (appointed to Compensation and Nominating & Governance) were elected; Mika Grasso designated audit committee financial expert.

Why It Matters
This filing signals material leadership turnover and potential financial exposure (≈$2.85M claimed severance) tied to disputed employment agreements and a lender‑related board reshuffle. Investors should watch the special‑counsel investigation outcome, any rulings about the alleged “Change in Control” and severance claims, the search for a permanent CFO, and how the new board composition affects corporate governance and strategic direction.